PMA device
GEM21S Growth Factor Enhanced Matrix
Lynch Biologics, LLC · Bone Grafting Material, Dental, With Biologic Component (NPZ, Class III) · First FDA decision Aug 29, 2008, newest Dec 4, 2020Gum diseaseTooth loss and dental implants
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
1
Naming "GEM21S Growth Factor"
MAUDE reports
0
Brand "GEM21S Growth Factor", since 2015
PubMed studies
0
Mentioning "GEM21S Growth Factor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing GEM21S Growth Factor Enhanced Matrix
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- GEM21S Growth Factor Enhanced MatrixPMA supplement
P040013-S024 · Decided Dec 4, 2020 · 231 days after receipt · Normal 180 Day Track No User Fee
Device type: Bone grafting material, dental, with biologic component (NPZ) · Dentistry & Oral Surgery
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "GEM21S Growth Factor", any status and sponsor, newest update first.
I-Ching WangAcademic, hospital or other
NCT06038695 · 0 participants · Start May 2025 · Primary completion Dec 2026
Device: Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB · For: Tooth Extraction; Immediate Implant Placement
Sites: Iowa City, Iowa
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "GEM21S Growth Factor", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NPZ
34 reports: 0 malfunction, 33 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "GEM21S Growth Factor"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NPZ.
- Infuse Bone GraftMedtronic, Inc. · PMA 2026
- Gem 21S Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2011
- Gem 21S (Growth Enhanced Matrix)Lynch Biologics, LLC · PMA 2008
- Pepgen P-15, Pepgen P-15 Flow & Pepgen P-15 PuttyCeramed Corp. · PMA 2007
- Pepgen P-15 Dental Bone Grafting Material with Biologic ComponentCeramed Corp. · PMA 2006
- GEM215 Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2020
- Gem 21SGROWTH Factor Enhanced MatrixLynch Biologics, LLC · PMA 2011
- Pepgen 15Ceramed Corp. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.